210 related articles for article (PubMed ID: 23933625)
1. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients.
Erkan D; Willis R; Murthy VL; Basra G; Vega J; Ruiz-Limón P; Carrera AL; Papalardo E; Martínez-Martínez LA; González EB; Pierangeli SS
Ann Rheum Dis; 2014 Jun; 73(6):1176-80. PubMed ID: 23933625
[TBL] [Abstract][Full Text] [Related]
2. Statins for the treatment of antiphospholipid syndrome?
Jajoria P; Murthy V; Papalardo E; Romay-Penabad Z; Gleason C; Pierangeli SS
Ann N Y Acad Sci; 2009 Sep; 1173():736-45. PubMed ID: 19758223
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.
Ferrara DE; Liu X; Espinola RG; Meroni PL; Abukhalaf I; Harris EN; Pierangeli SS
Arthritis Rheum; 2003 Nov; 48(11):3272-9. PubMed ID: 14613293
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells.
Ferrara DE; Swerlick R; Casper K; Meroni PL; Vega-Ostertag ME; Harris EN; Pierangeli SS
J Thromb Haemost; 2004 Sep; 2(9):1558-63. PubMed ID: 15333031
[TBL] [Abstract][Full Text] [Related]
5. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
6. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort.
Willis R; Seif AM; McGwin G; Martinez-Martinez LA; González EB; Doan E; Dang N; Papalardo E; Liu J; Vilá LM; Reveille JD; Alarcón GS; Pierangeli SS
Clin Exp Rheumatol; 2014; 32(2):162-7. PubMed ID: 24480124
[TBL] [Abstract][Full Text] [Related]
7. Clinical associations of proinflammatory cytokines, oxidative biomarkers and vitamin D levels in systemic lupus erythematosus.
Willis R; Smikle M; DeCeulaer K; Romay-Penabad Z; Papalardo E; Jajoria P; Harper B; Murthy V; Petri M; Gonzalez EB
Lupus; 2017 Dec; 26(14):1517-1527. PubMed ID: 28467291
[TBL] [Abstract][Full Text] [Related]
8. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome.
López-Pedrera C; Ruiz-Limón P; Aguirre MÁ; Barbarroja N; Pérez-Sánchez C; Buendía P; Rodriguez-García IC; Rodriguez-Ariza A; Collantes-Estevez E; Velasco F; Khasmahta M; Cuadrado MJ
Ann Rheum Dis; 2011 Apr; 70(4):675-82. PubMed ID: 21173016
[TBL] [Abstract][Full Text] [Related]
9. Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state.
Swadzba J; Iwaniec T; Musial J
Rheumatol Int; 2011 Mar; 31(3):307-13. PubMed ID: 20012959
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.
Ruiz-Limon P; Barbarroja N; Perez-Sanchez C; Aguirre MA; Bertolaccini ML; Khamashta MA; Rodriguez-Ariza A; Almadén Y; Segui P; Khraiwesh H; Gonzalez-Reyes JA; Villalba JM; Collantes-Estevez E; Cuadrado MJ; Lopez-Pedrera C
Ann Rheum Dis; 2015 Jul; 74(7):1450-8. PubMed ID: 24658835
[TBL] [Abstract][Full Text] [Related]
11. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype.
Meroni PL; Raschi E; Testoni C; Tincani A; Balestrieri G; Molteni R; Khamashta MA; Tremoli E; Camera M
Arthritis Rheum; 2001 Dec; 44(12):2870-8. PubMed ID: 11762948
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies.
Forastiero RR; Martinuzzo ME; de Larrañaga GF
Lupus; 2005; 14(2):129-36. PubMed ID: 15751817
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.
Kim KJ; Baek IW; Yoon CH; Kim WU; Cho CS
Clin Exp Rheumatol; 2017; 35(5):823-830. PubMed ID: 28421990
[TBL] [Abstract][Full Text] [Related]
14. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
15. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation.
Hisada R; Kato M; Sugawara E; Kanda M; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Yasuda S; Atsumi T
J Thromb Haemost; 2019 Jul; 17(7):1134-1143. PubMed ID: 30864219
[TBL] [Abstract][Full Text] [Related]
16. Serological evolution in women with positive antiphospholipid antibodies.
Riancho-Zarrabeitia L; Daroca G; Muñoz P; López-Hoyos M; Haya A; Martínez-Taboada VM
Semin Arthritis Rheum; 2017 Dec; 47(3):397-402. PubMed ID: 28576307
[TBL] [Abstract][Full Text] [Related]
17. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
Front Immunol; 2019; 10():885. PubMed ID: 31134052
[TBL] [Abstract][Full Text] [Related]
18. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells.
Pierangeli SS; Harris EN
Lupus; 2003; 12(7):539-45. PubMed ID: 12892395
[TBL] [Abstract][Full Text] [Related]
19. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
[TBL] [Abstract][Full Text] [Related]
20. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.
Idborg H; Zandian A; Sandberg AS; Nilsson B; Elvin K; Truedsson L; Sohrabian A; Rönnelid J; Mo J; Grosso G; Kvarnström M; Gunnarsson I; Lehtiö J; Nilsson P; Svenungsson E; Jakobsson PJ
Arthritis Res Ther; 2019 Feb; 21(1):62. PubMed ID: 30777133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
